Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma

BACKGROUND: Rhabdomyosarcoma (RMS) is a paediatric cancer driven either by fusion proteins (e.g., PAX3-FOXO1) or by mutations in key signalling molecules (e.g., RAS or FGFR4). Despite the latter providing opportunities for precision medicine approaches in RMS, there are currently no such treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorito, Elisa, Szybowska, Patrycja, Haugsten, Ellen M., Kostas, Michal, Øy, Geir F., Wiedlocha, Antoni, Singh, Sachin, Nakken, Sigve, Mælandsmo, Gunhild M., Fletcher, Jonathan A., Meza-Zepeda, Leonardo A., Wesche, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681859/
https://www.ncbi.nlm.nih.gov/pubmed/36097178
http://dx.doi.org/10.1038/s41416-022-01973-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681859/
https://www.ncbi.nlm.nih.gov/pubmed/36097178
http://dx.doi.org/10.1038/s41416-022-01973-6

Ejemplares similares